Blinatumomab

Blinatumomab is a type of targeted cancer therapy called a bi-specific T-cell engager (BiTE). It is designed to help the immune system recognize and attack certain cancer cells, specifically in cases like acute lymphoblastic leukemia (ALL). Blinatumomab works by binding to both cancer cells and T-cells (a type of immune cell), bringing them into close contact. This proximity prompts the T-cells to release chemicals that destroy the cancer cells. It’s administered via continuous infusion and is used for patients with specific types of blood cancer, especially when other treatments haven't been effective.